Activate Now
 
ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Patient Insights into the Design of Technology to Support a Strengths-Based Approach to Health Care.

Greater intake of dietary omega-3 fatty acids associated with lower risk of diabetic retinopathy

SURVEY: Weight Management & Chronic Illness

Japanese green tea consumers have reduced risk of dementia

Do Nothing, Accomplish Everything! The Connection Between Breathing and Healing

Best Herbs to Help With Insomnia

Nature Heals

Meet the ProHealth Editors

Choline: Why You Should Eat Your Egg Yolks and Take Krill

Calcium, vitamin D supplementation associated improved stroke recovery

 
Print Page
Email Article

Hemispherx Biopharma Reports Publication Suggesting Efficacy of Ampligen in Treating Myocarditis Virus

  [ 58 votes ]   [ Discuss This Article ]
www.ProHealth.com • January 26, 2004


January 26, 2004 10:00 AM US Eastern Timezone PHILADELPHIA--(BUSINESS WIRE)--Jan. 26, 2004-- Data Show Ampligen Superior to Both Recombinant and Pegelated Interferons for Life - Threatening Inflammation of the Heart Hemispherx Biopharma, Inc. (AMEX: HEB) announced today that the results from an independent study, conducted by Professor Johan Neyts of the Rega Institute, KUL, Leuven Belgium, have been publicized in "Antimicrobial Agents and Chemotherapy", Jan. 2004, Vol 48, p. 267 - 274. The study, "The Interferon Inducer Ampligen Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis." was conducted in an animal model of human disease and suggests that Hemispherx's Ampligen(R) was effective in treating Coxsackie virus. The Coxsackie virus causes a fulminant myocarditis, which is a life threatening inflammation of the heart. The treatment with the experimental compound Ampligen(R) decreased inflamed foci by approximately 98% and was 10 times superior to recombinant interferon (rIFN) and 15 times better than pegelated interferon (PEG-IFN). Viral concentrations in the heart were decreased more than 99% by Ampligen(R) and serial EKGs evidenced much improved cardiac performance by Ampligen(R) treatment. rIFN and PEG-IFN are the present world-wide standard of care in several major human viral infections. About Ampligen(R) Ampligen(R) is an experimental, double stranded RNA product acting potentially as an immunomodulator and antiviral. The product is currently in Phase 3 clinical trial for the treatment of Chronic Fatigue Syndrome and in two Phase 2b clinical trials for the treatment of HIV/AIDS. About Hemispherx Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 400 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N(R)) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R) and Oragens(TM)) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications including SARS. The Alferon(R) asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations. Contacts Hemispherx Biopharma, Inc.
Investor Relations:
Dianne Will, 518/398-6222
ir@hemispherx.net
www.hemispherx.net
or
CEOcast
Cormac Glynn, 212/732-4300
cglynn@ceocast.com



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS
Coping When Colds or Flu Catch Up with You Coping When Colds or Flu Catch Up with You
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE AND SAVE 15% NOW*
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map